Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Abstract Text:

Mark Bishton,Melita Kenealy,Ricky Johnstone,Walid Rasheed,H Miles Prince,

Chromatin modeling in DNA is fundamental to gene expression, DNA repair and replication. Methylation of promoter regions of tumor-suppressor genes and histone deacetylation leads to gene silencing and transcriptionally repressive chromatin. Histone deacetylase inhibitors and hypomethylating agents allow upregulation of proapoptotic genes and downregulation of antiapoptotic genes, and show significant single-agent anticancer activity, predominantly in cutaneous T-cell lymphoma and myelodysplasia, respectively. Combinations of these drugs are being employed in clinical trials to target multiple biological pathways, with the hope of synergistic pharmacodynamics. Preclinical studies of combinations of these agents with chemotherapy, monoclonal antibodies and small-molecule inhibitors are ongoing and demonstrate synergy in multiple hematological cancers, raising the prospect of future treatment for these diseases having a multitargeted approach.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Publishing Authors By Initials

M Bishton,M Kenealy,R Johnstone,W Rasheed,HM Prince,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert review of anticancer therapy

VOLUME: 7

Page Numbers: 1439-49

Journal Abbreviation: Expert Rev Anticancer Ther

ISSN: 1744-8328

DAY: 5

MONTH: Oct

YEAR: 2007

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Information

Number of References: 100

LANGUAGE: eng

NlmUniqueID: 101123358

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

AFFILIATION: Peter MacCallum Cancer Center, Department of Haematology, Melbourne, Australia. mark.bishton@petermac.org

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Rev Anticancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents Related Publications

• A new satellite technology for tracking the movements of atlantic bluefin tuna.
• A role for Tbx2 in the regulation of the alpha2(1) collagen gene in human fibroblasts.
• An advance in colour photomicrography of the living eye.
• Automatic 3D tracking of cardiac material markers using slice-following and harmonic-phase MRI.
• Bone mass in young women is dependent on lean body mass.
• Comparison of speech production in upright and supine position.
• Consequences of Hoxb1 duplication in teleost fish.
• Cortical surface alignment using geometry driven multispectral optical flow.
• Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
• Fatty acids ofLindera umbellata and other Lauraceae seed oils.
• Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.
• Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
• Is there replacement for percentage stenosis in characterizing occlusive vascular disease?
• Markers of inflammation and cognitive decline in an African-Caribbean population.
• Multi-slice three-dimensional myocardial strain tensor quantification using zHARP.
• Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis.
• Origin of the zebrafish endocrine and exocrine pancreas.
• Pathways to homelessness among older people in Rio de Janeiro, Brazil.
• Prevalence of depressive symptoms and syndromes in later life in ten European countries: the SHARE study.
• Real-time monitoring of cardiac regional function using fastHARP MRI and region-of-interest reconstruction.
• Safety and efficacy of combining ATRA with G-CSF in HSPC mobilization; a pilot study in multiple myeloma and non-Hodgkin's lymphoma patients.
• Staphylococcus aureus protein A activates TACE through EGFR-dependent signaling.
• Successful treatment of Behçet's disease with lenalidomide.
• Tea drinking is associated with benefits on bone density in older women.
• Tea intake is inversely related to blood pressure in older women.
• Toward optimal matching for 3D reconstruction of brachytherapy seeds.
• Treatment of primary cutaneous follicular centre lymphoma with rituximab: A report of two cases.
• ZHARP: three-dimensional motion tracking from a single image plane.
• Zebrafish Hoxb1a regulates multiple downstream genes including prickle1b.
• [Stress and prevention in the recurrence of coronary heart disease.]